Demonstration of neutralizing mucosal IgA response to intranasal HIV-1 env DNA vaccines with or without the V3 glycosylation site

Scandinavian Journal of Infectious Diseases

Volumn 36, Issue 5, 2004, Pages 360-364

  Rowcliffe, Eric ^a   Bolmstedt, Anders ^a   Biller, Marlene ^a   Wahren, Britta ^b   Olofsson, Sigvard ^a   Hinkula, Jorma ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GLYCAN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; PLASMID DNA; PROTEIN ANTIBODY; RECOMBINANT GLYCOPROTEIN GP 160; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; DRUG ACTIVITY; FECES ANALYSIS; FEMALE; GLYCOSYLATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOMODULATION; LUNG LAVAGE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN;

ADMINISTRATION, INTRANASAL; AIDS VACCINES; ANIMALS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOSYLATION; IMMUNITY, CELLULAR; IMMUNOGLOBULIN A; MICE; MICE, INBRED BALB C; NASAL MUCOSA; NEUTRALIZATION TESTS; PROBABILITY; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; VACCINES, DNA;

EID: 3242816120     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540410020208     Document Type: Article

References (21)

1. Liu MA. DNA vaccines: a review. J Intern Med 2003; 253: 402-10.
2. Robinson HL. New hope for an AIDS vaccine. Nat Rev Immunol 2002; 2: 239-50.
3. Ulmer JB. Influenza DNA vaccines, Vaccine 2002; 20 (Suppl 2): S74-6.
4. Hooper JW, Custer DM, Thompson E, Schmaljohn CS. DNA vaccination with the Hantaan virus M gene protects hamsters against 3 of 4 HFRS hantaviruses and elicits a high-titre neutralizing antibody response in Rhesus monkeys. J Virol 2001; 75: 8469-77.
5. Bernstein DI, Stanberry LR. Herpes simplex virus vaccines. Vaccine 1999; 17: 1681-9.
6. Corbet S, Vinner L, Hougaard DM, Bryder K, Nielsen HV, Nielsen C, Fomsgaard A. Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on a primary, CCR5-tropic, early HIV type 1 isolate (BX08) with human codons. AIDS Res Hum Retroviruses 2000; 16: 1997-2008.
7. Bolmstedt A, Hinkula J, Rowcliffe E, Biller M, Wahren B, Olofsson S. Enhanced immunogenicity of a human immunodeficiency virus type 1 env DNA vaccine by manipulating N-glycosylation signals. Effects of elimination of the V3 N306 glycan. Vaccine 2001; 20: 397-405.
8. Schønning K, Jansson B, Olofsson S, Nielsen J O, Hansen J S. Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quartenary structure of the HIV-1 envelope oligomer. Virology 1996; 218: 134-40.
9. Bomsel M. Transcytosis of infectious human immunodeficiency virus a cross a tight human epithelial cell line barrier. Nat Med 1997; 3: 42-7.
10. Wahren B, Hinkula J, Stahle EL, Borrebaeck CA, Schwartz S, Wigzell H. Nucleic acid vaccination with HIV regulatory genes. Ann N Y Acad Sci 1995; 772: 278-81.
11. Ljungberg K, Rollman E, Erikson L, Hinkula J, Wahren B. Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology 2002; 302: 44-57.
12. Lundholm P, Asakura Y, Hinkula J, Lucht E, Wahren B. Induction of mucosal IgA by a novel jet delivery technique for HIV-1 DNA. Vaccine 1999; 17: 2036-42.
13. Åkerblom L, Hinkula J, Broliden PA, Mäkitalo B, Fridberger T, Rosen J, et al. Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120. Aids 1990; 4: 953-60.
14. Devito C, Levi M, Hinkula J, Fernandez Medina RD, Libonatti O, Wigzell H. Seroreactivity to HIV-1 V3 subtypes A to H peptides of Argentinian HIV-positive sera. J Acquired Immune Defic Syndr Hum Retroviruses 1998; 17: 156-9.
15. Kuiken C, Foley B, Hahn B, Marx P, McCutchan F, Mellors J, et al., eds. HIV Sequence Compendium 2002. Los Alamos: Los Alamos National Laboratory; 2001.
16. Yan H, Lamm ME, Bjorling E, Huang YT. Multiple functions of immunoglobulin A in mucosal defence against viruses: an in vitro measles virus model. J Virol 2002; 76: 10972-9.
17. Vinner L, Nielsen HV, Bryder K, Corbet S, Nielsen C, Fomsgaard A. Gene gun DNA vaccination with rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons. Vaccine 1999; 17: 2166-75.
18. Binley JM, Sanders RW, Clas B, Schuelke N, Master A, Guo Y, et al. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion- associated structure. J Virol 2000; 74: 627-43.
19. Earl PL, Sugiura W, Montefiori DC, Broder CC, Lee SA, Wild C, et al. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol 2001; 75: 645-53.
20. Schulke N, Vesanen MS, Sanders RW, Zhu P, Lu M, Anselma DJ, et al. Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. J Virol 2002; 76: 7760-76.
21. Yang X, Florin L, Farzan M, Kolchinsky P, Kwong PD, Sodroski J, Wyatt R. Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution. J Virol 2000; 74: 4746-54.